> 首页 > 产品 > 一抗 > 其他 > Anti-CD3 & GD2 Reference Antibody (Nivatrotamab)

Anti-CD3 & GD2 Reference Antibody (Nivatrotamab)

Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00%, determined by SEC-HPLC.
Nivatrotamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to huCD3e-jurkat cells, and the EC50 was 3.481 nM.
Nivatrotamab bound to hu GD2-293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to hu GD2-293 cells, and the EC50 was 68.100 nM.
Co-incubation of Nivatrotamab with Jurkat cells, then with the addition of hu GD2-his-293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Nivatrotamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.979 nM.
The detected molecular weight of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 200.83 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P07766 & NA
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-scFv

Additional Information
Target/Specificity	CD3,GD2
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.